Cart
sales@molnova.com
4,4-Iminodiphenol
CAS No. 1752-24-5
4,4-Iminodiphenol( Leucoindophenol )
Catalog No. M26540 CAS No. 1752-24-5
4,4'-Iminodiphenol is an inactive estrogen receptor ligand with a diphenylamine backbone.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 25MG | 29 | In Stock |
|
| 50MG | 37 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name4,4-Iminodiphenol
-
NoteResearch use only, not for human use.
-
Brief Description4,4'-Iminodiphenol is an inactive estrogen receptor ligand with a diphenylamine backbone.
-
Description4,4'-Iminodiphenol is an inactive estrogen receptor ligand with a diphenylamine backbone.
-
In Vitro——
-
In Vivo——
-
SynonymsLeucoindophenol
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1752-24-5
-
Formula Weight201.225
-
Molecular FormulaC12H11NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOc1ccc(Nc2ccc(O)cc2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Patel A, Li TW, Anreddy N, Wang DS, Sodani K, Gadhia S, Kathawala R, Yang DH, Cheng C, Chen ZS. Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. Pharmacol Res. 2017 Jul;121:184-193.
molnova catalog
related products
-
glutamic acid
(S)-Glutamic acid acts as an excitatory transmitter, shows a direct activating effect on the release of DA from dopaminergic terminals.
-
Medicarpin (b)
(+)-Medicarpin potently inhibits osteoclastogenesis and promotes bone healing and increases bone mass by osteoblast differentiation with estrogen receptor (ER) β-mediated osteogenic action.
-
H3B-5942
H3B-5942 is an orally available, selective estrogen receptor covalent antagonist (SERCA), demonstrates potent ERαantagonist activity in vitro and in vivo.
